Zucara Therapeutics
Location: Canada, Ontario, Toronto
Total raised: $70.25M
Investors 2
| Date | Name | Website |
| - | adMare Bio... | admarebio.... |
| 02.11.2022 | Xontogeny | xontogeny.... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 02.05.2025 | Series B | $25M | - |
| 12.11.2024 | Series B | $20M | - |
| 31.03.2020 | Series A | $21M | - |
| 10.04.2018 | - | $3.9M | - |
| - | - | $350K | - |
Mentions in press and media 12
| Date | Title | Description |
| 03.05.2025 | Zucara Therapeutics Secures $25 Million to Combat Diabetes Complications | Zucara Therapeutics is on a mission. The Toronto-based company is tackling a significant challenge in diabetes management: hypoglycemia. Recently, Zucara completed its Series B financing, raising a total of $25 million. This funding is a li... |
| 02.05.2025 | Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences Platform | Zucara Therapeutics – a diabetes life sciences company developing ZT-01, which is the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes – announced that it has completed the second and f... |
| 01.05.2025 | Zucara Therapeutics Raises $5M in Second and Final Closing of US$25M Series B Financing | Zucara Therapeutics Inc., a Toronto, Canada-based diabetes life sciences company, raised $US5m in the second and final closing of its US$25m Series B financing. The T1D Fund: A Breakthrough T1D Venture, and other new investors invested a co... |
| 12.11.2024 | Zucara Therapeutics Raises US$20M in Series B Financing | Zucara Therapeutics, a Toronto, Canada-based diabetes life sciences company, raised US$20M in Series B funding. The round was led by Sanofi (As part of the agreement, the company will receive an exclusive right of first negotiation) and The... |
| 02.05.2022 | adMare Portfolio Company, Zucara Therapeutics Secures Additional Funding for the Development of ZT-01 | Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has received s... |
| 08.02.2022 | adMare Portfolio Company, Zucara Therapeutics Announces Publication of Preclinical Study | Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that the peer-rev... |
| 02.11.2020 | Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes | – ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding – Toronto, Canada, November 2, 2020 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily... |
| 03.04.2020 | Daily funding roundup - April 2nd, 2020 | Jenny Life raised $3.5M; SteadyMD closed $6M; Zucara Therapeutics landed $21M Atmosphere Atmosphere is a streaming TV service for businesses. Atmosphere has raised $5 million in fresh Series A funding that brings the total round to $14 mill... |
| 31.03.2020 | Zucara Therapeutics, an adMare & TIAP Spin-off Company, Announces $21M Series A Financing | Toronto, Canada – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million ... |
| 10.04.2018 | Zucara Therapeutics Secures US$3.9M in Non-Dilutive Funding | Zucara Therapeutics Inc., a Canadian diabetes life sciences company advancing once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), secured US$3.9m in non-dilutive funding. The Leona M. and Harry B. Helmsley Charitable ... |
Show more